Policy & Regulation

Nine Jiangsu provincial departments in eastern China led by the Department of Industry and Information Technology issued the Action Plan for Innovative Development of the Brain-Computer Interface Industry in Jiangsu in March 2026, implementing national guidance from seven ministries. Its most distinctive provision covers industrial deployment, directing firms in hazardous materials, nuclear power, mining and electricity to pilot BCI systems in safety management and deep-sea and deep-pit operations, sectors no other provincial document names. Headline goals are at least two provincial clusters by 2027 and two to three leading enterprises by 2030. Its quantitative targets sit at the end of 14 tasks and all fall in 2030, including at least 15 programme projects, 15 key technology tasks, about 10 innovation platforms, 30 certified flagship products, 20 registered medical devices and a dataset of at least 20,000 samples.

Four Chinese ministries jointly issued science-technology insurance guidance, listing BCI alongside AI and quantum technology as key sectors for dedicated insurance products.

The FDA cleared Clouds of Care's PreOp v3 on February 13, 2026, finding it substantially equivalent under submission number K252565 through the special 510(k) pathway. The agency classifies it as Source Localization Software for Electroencephalograph or Magnetoencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Source localization software infers the intracranial origin of signals from scalp-recorded electric or magnetic fields, a step in neurosurgical planning such as presurgical localization of epileptic foci.

Alphatec Spine's SafeOp 3 neural monitoring system received FDA 510(k) clearance on January 11, 2026 for intraoperative neural monitoring. The device is regulated as a Class II "Stimulator, Electrical, Evoked Response" under regulation number 882.1870, and the clearance came through the traditional 510(k) pathway, with the FDA finding the device substantially equivalent to a predicate device. Alphatec Spine, a maker of spinal surgery devices and technologies, adds SafeOp 3 to its neural monitoring portfolio; the system is intended to let surgeons assess nerve function in real time during procedures and lower the risk of nerve injury.

BrainCo's FocusXin Medical Edition combines a single-channel prefrontal EEG device registered as 浙械注准20232071898 with ADHD rehabilitation software registered as 浙械注准20252211934. The Class II system is intended for supplementary rehabilitation training in children aged 6 to 12 with ADHD. Its defined medical use should not be generalized into approval for an unspecified consumer BCI product.

The FDA cleared the Ceribell Delirium Monitor System on December 8, 2025, finding it substantially equivalent under submission number K251936 through the traditional 510(k) pathway. The agency classifies it as a Neuropsychiatric Interpretative Electroencephalograph Assessment Aid, a Class II device under regulation 882.1440, with neurology as the assigned review panel. The category covers devices that derive neuropsychiatric assessments from EEG signals; Ceribell's earlier products in this line target seizure monitoring in emergency and intensive care settings.

Tongji Hospital in Wuhan implanted a 64-channel high-throughput flexible electrode array made by Wuhan Neuracom into a 31-year-old man paralysed by a spinal cord injury on 26 November 2025. The procedure was charged under the country's first BCI medical service price schedule, issued by Hubei's healthcare security bureau in March 2025, which sets implantation at 6,552 yuan. China's National Healthcare Security Administration calls it the first BCI operation in the country carried out under a state-set price. This patient's costs were covered by research funding.

The FDA cleared Hippoclinic's HippoMind, version 1.0, on December 3, 2025, finding it substantially equivalent under submission number K251881 through the traditional 510(k) pathway. The agency classifies it as Non-Normalizing Quantitative Electroencephalograph Software, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Unlike normalizing tools, non-normalizing quantitative EEG software reports an individual's own EEG metrics without reference to a population database.

The General Office of China's Jiangxi Provincial People's Government issued Several Measures for Accelerating the Development of Brain-Computer Interface Technology and Industry in Jiangxi on November 26, 2025, document number Gan Fu Ting Fa [2025] No. 29, setting out 11 measures across four areas. It was the first provincial document to follow the seven-ministry national guidance and is the only one that sets no quantitative industry targets at all. Its eleventh measure calls for implementing BCI research ethics guidelines and establishing mutual recognition of clinical research ethics review, a first among provincial documents. Other measures deploy a provincial major science and technology programme, back Ganjiang New Area in building a rehabilitation centre and a high-quality EEG dataset, and offer early regulatory engagement plus rewards for Class II and Class III innovative device approvals.

The FDA cleared Naox Technologies' NX01 on November 25, 2025, finding it substantially equivalent under submission number K251550 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Reduced-montage systems record with fewer electrodes than a conventional clinical montage, trading spatial resolution for faster setup and the possibility of wearable form factors.

The US Food and Drug Administration cleared Ceribell, Inc.'s Ceribell Infant Seizure Detection Software on November 21, 2025, finding it substantially equivalent under submission number K252070 via the Traditional 510(k) pathway. FDA lists it as Automatic Event Detection Software for Full-Montage Electroencephalograph, a Class II device under regulation number 882.1400, reviewed by the agency's neurology advisory committee. Neonatal EEG looks markedly different from adult morphology, which has long made automated interpretation difficult; the classification covers software that flags events automatically in full-montage recordings.

UNESCO's 43rd General Conference adopted the Recommendation on the Ethics of Neurotechnology, the first global framework, backed by 194 Member States.

The FDA cleared Persyst Development's Persyst 15 EEG Review and Analysis Software on October 31, 2025, finding it substantially equivalent under submission number K252160 through the traditional 510(k) pathway. The agency classifies it as Automatic Event Detection Software for Full-Montage Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. The category covers software that automatically flags events within full-montage EEG recordings for clinician review.

Nihon Kohden's EEG-1260A Neurofax system, along with its amplifier unit and photic stimulator, received FDA 510(k) clearance on October 9, 2025. The device is a Class II medical device in the neurology specialty, with software for quantitative EEG analysis. The traditional 510(k) clearance indicates substantial equivalence to a legally marketed device.

ARC-EX is a non-invasive spinal cord stimulation device used to improve hand function in people with spinal cord injury; the CE mark allows commercial sale in the EU.

The FDA cleared Forest Devices' SignalNED System (Model RE) on September 3, 2025, finding it substantially equivalent under submission number K251726 through the traditional 510(k) pathway. The agency classifies it as a Reduced-Montage Standard Electroencephalograph, a Class II device under regulation 882.1400, with neurology as the assigned review panel. Forest Devices has applied reduced-montage EEG to prehospital stroke identification, acquiring interpretable signals in settings such as ambulances.

Thirteen departments in China's Shandong province, led by the Department of Science and Technology, jointly issued the Action Plan for Scientific and Technological Innovation in the Brain-Computer Interface Industry in Shandong (2025-2027), document number Lu Ke Zi [2025] No. 50, dated May 13, 2025 and released on May 16. By 2027 the province aims for roughly 20 breakthroughs in frontier and core technologies, about 30 innovative technology SMEs, two to three high-level talent teams, and one to two specialised incubators in areas rich in research and education resources, with applications reaching medicine, industry, elderly care, education and entertainment. By 2030 it expects an initial BCI industry ecosystem. The plan organises work into six campaigns and backs Jinan and Qingdao as innovation clusters. It is the first of Shandong's two provincial BCI documents and covers the industrial side.

Eight Sichuan provincial departments in southwestern China led by the Department of Economy and Information Technology issued the Action Plan for Breakthroughs in the Brain-Computer Interface and Human-Machine Interaction Industry in Sichuan (2025-2030) on May 12, 2025. The plan is unusual in making surgical volume a headline metric, targeting 3,000 invasive BCI procedures a year by 2030, along with services for more than 100,000 patients a year with neurodegenerative disease, psychiatric conditions and drug or digital addiction, and rehabilitation device use exceeding 20,000 sessions a year. By 2027 it aims to complete development and medical device registration of three invasive and five non-invasive products, carry out the province's first invasive BCI operation, serve more than 50,000 patients a year, and cultivate 10 chain-leading firms, 100 specialised SMEs and 200 innovative smaller enterprises. Chengdu, Mianyang, Deyang and Nanchong are named as host cities.

Shanghai's science commission issued a BCI industry action plan centering on medical-grade scenarios, with a clinical timeline for invasive and semi-invasive products.

Three Beijing agencies jointly issued a BCI action plan targeting 3-5 globally influential leaders and around 100 innovative SMEs by 2030.

California's SB 1223, enacted in 2024, amended the CCPA to classify neural data as sensitive personal information alongside genetic and biometric data.

Colorado's HB24-1058, signed in 2024, brought neural data under the state privacy act's sensitive-data protections, a first in the United States.

The US Bureau of Industry and Security announced a two-day hybrid BCI conference with industry and academic experts, following its 2021 export-control inquiry.

The FDA granted Breakthrough Device designation to Blackrock Neurotech's MoveAgain BCI System on November 16, 2021. The investigational system combines an implanted array, neural decoding and wireless output with the goal of allowing people with severe paralysis to control digital and assistive devices. The designation can expedite development and review but is not market approval.

The US Bureau of Industry and Security published a 2021 advance notice seeking comments on export controls for BCI as an emerging technology, focused on national security.

Chile's Ley 21.383, published in 2021, amended Article 19 of the Constitution to require special protection of brain activity, a world first.

The FDA issued final guidance in 2021 on implanted brain-computer interface (BCI) devices for patients with paralysis or amputation, covering nonclinical testing and clinical study design.

The OECD Council adopted the Recommendation on Responsible Innovation in Neurotechnology in December 2019, guiding governments with nine principles.